UCB, Inc. is a biopharmaceutical company that develops and sells drugs. Its filings show it lobbies on tax rules (including international tax talks and the global minimum tax), prescription drug issues (like step therapy, copays, and pharmacy benefit manager reforms), and trade matters such as tariffs. The filings are recent and total about $240,000 across four reports.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
BRETT BAKER
The latest disclosures for this client.
THE NICKLES GROUP, LLC
Q4THE NICKLES GROUP, LLC
Q3The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
THE NICKLES GROUP, LLC
GREG D'ANGELO
THE NICKLES GROUP, LLC
MARY BETH SAVARY TAYLOR
THE NICKLES GROUP, LLC
RACHEL JONES HENSLER
THE NICKLES GROUP, LLC
THE NICKLES GROUP, LLC
Q2THE NICKLES GROUP, LLC
Q1